^
Association details:
| Biomarker: | EGFR L858R + PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
342P - Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Published date:
11/28/2022
Excerpt:
30 mNSCLC with EGFR mutation, PDL1, & TPS analyses were enrolled....Exon19 MT with low & high PDL1 TPS mOS were ≥ 969d & 478d (p= 0.08), respectively. Exon21 MT with low & high PDL1 TPS mOS were ≥888d & 345d, p=0.22, respectively. Erlotinib & Gefitinib achieved higher mPFS trend [874d & 311d (p= 0.21), respectively]...Erlotinib & Osimertinib had higher mOS trend (both ≥969d, p=0.5), followed by Gefitinib & Afatinib with mOS of ≥ 888d & 150d (p= 0.034), respectively....Exon19 del & exon21 L858R MT with low PD-L1 TPS had the most favorable PFS & OS compared to their mutant high PD-L1 TPS & PD-L1 negative counterparts. In addition, Erlotinib treatment had the most favorable PFS & OS compared to other TKIs. Exon19 deletion & exon21 L858R strongly correlates with Gefitinib & Erlotinib treatments, respectively.
